Literature DB >> 31785401

HepCare Europe-A service innovation project. HepCheck: Characteristics of the patient population with active infection as defined by HCV RNA.

Gordana Avramovic1, Cristiana Oprea2, Julian Surey3, Alistair Story4, Juan Macías5, Walter Cullen6, Maria Iglesias5, Tina Mc Hugh7, Des Crowley8, Anna Marie Naughton8, Aidan Horan8, Irina Ianache2, Stefan Lazar2, Ionut Popa2, Dee Menezes3, John S Lambert9.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) is a main cause of chronic liver disease worldwide and is consistently under-diagnosed. Community-based screening initiatives, such as HepCheck, have been identified as important components of HCV care. HepCheck focuses on screening and identifying HCV RNA-positive cases in high-risk populations and linking them to care as part of a larger European project to improve HCV care (HepCare).
METHODS: HCV testing with a self-administered questionnaire was offered to 2822 individuals.
RESULTS: There were 2079 patients screened. Overall, 397 (19%) of the total screened cohort were identified as having active HCV infections as measured by HCV RNA PCR. The patients were mostly male (84%), white (88%), and had a history of injecting drug use (IDU) (86%), homelessness (58%), and tattooing (42%). There were 136 new cases (7% of the total sample and 34% of identified active infections). Romania had the highest proportion of newly identified cases with 87%, then Ireland with 60%, and Spain with 43%; the UK had the lowest proportion of new cases at 10%.
CONCLUSIONS: For those lost to follow-up, a major strategy is re-engagement. For those newly diagnosed, the 'seek and treat' approach is a key strategy. Thus, different priorities are defined for different countries.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Hepatitis C; Homeless; Integrated HCV care; People who inject drugs (PWID); Prisoners; Screening; Vulnerable populations

Mesh:

Substances:

Year:  2019        PMID: 31785401     DOI: 10.1016/j.ijid.2019.11.027

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  6 in total

1.  Dermatological and Ophthalmological Inflammatory, Infectious, and Tumoral Tattoo-Related Reactions: A Systematic Review.

Authors:  Juliana Muñoz-Ortiz; Mariana Teresa Gómez-López; Paula Echeverry-Hernández; Mario Federico Ramos-Santodomingo; Alejandra de-la-Torre
Journal:  Perm J       Date:  2021-05-26

Review 2.  HepCare Ireland-a service innovation project.

Authors:  Stephen P Connolly; Gordana Avramovic; Walter Cullen; Tina McHugh; Eileen O'Connor; Geoff Mc Combe; Des Crowley; Anna Marie Naughton; Aidan Horan; John S Lambert
Journal:  Ir J Med Sci       Date:  2020-08-06       Impact factor: 1.568

3.  Exploring and understanding HCV patient journeys- HEPCARE Europe project.

Authors:  Shannon Glaspy; Gordana Avramovic; Tina McHugh; Cristiana Oprea; Julian Surey; Irina Ianache; Juan Macías; Alistair Story; Walter Cullen; John S Lambert
Journal:  BMC Infect Dis       Date:  2021-03-05       Impact factor: 3.090

4.  An experience using historical hepatitis C data to Re-Engage: Possibilities and pitfalls during the COVID-19 pandemic.

Authors:  William Osborne; Noorann Sheikh; Gemma Botterill; Sally Bufton; David Mutimer; Mamoona Tahir; Sowsan F Atabani
Journal:  Public Health Pract (Oxf)       Date:  2021-10-23

5.  Blood Glucose and Renal Function Evaluation in Patients with Viral Hepatitis.

Authors:  Wen-Tung Hsu; Deng-Ho Yang; Chun-Cheng Liao; Jia-Wen Chen; Wen-Hsiu Hsu; Chia-Wen Kuo; Hung-Chang Hsu; Sheng-Huang Chang; Li-Mien Chen
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-20       Impact factor: 3.168

6.  A Feasibility Study to Increase Chronic Hepatitis C Virus RNA Testing and Linkage to Care among Clients Attending Homeless Services in Amsterdam, The Netherlands.

Authors:  Ellen Generaal; Hilje Logtenberg van der Grient; Eberhard Schatz; Daniela K van Santen; Anders Boyd; Sara K Woods; Bert L C Baak; Maria Prins
Journal:  Diagnostics (Basel)       Date:  2021-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.